Form 4: Avidity Biosciences Director Sells Shares to Cover Tax Obligations

Avidity Biosciences director Arthur A. Levin sold 1,872 shares of common stock on January 21, 2025, to cover tax obligations related to vesting of restricted stock units.

Summary

• Arthur A. Levin, a director at Avidity Biosciences, sold 1,872 shares of common stock on January 21, 2025.
• The sale was executed to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs) on January 20, 2025.
• The shares were sold at a weighted-average price of $28.5987, with individual transactions ranging from $28.59 to $29.94.
• Following the transaction, Levin directly owns 12,958 shares and indirectly owns 131,372 shares through a family trust.
• The sale was not a discretionary trade but was mandated by the company's equity incentive plan's sell-to-cover policy.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction related to executive compensation and does not indicate any positive or negative sentiment.

Industry Context

This is a routine transaction related to executive compensation and tax obligations, common in publicly traded companies.

Comparison to Industry Standards

• Sell-to-cover transactions are a standard practice for companies with equity compensation plans.
• The price range of $28.59 to $29.94 is within the expected range for a stock sale of this type.
• Similar transactions are regularly reported by directors and officers of other publicly traded companies.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a routine sale to cover tax obligations.

Key Dates

Keywords

Avidity Biosciences, Director, Share Sale, Tax Obligations, Restricted Stock Units, Sell-to-Cover, Form 4, Insider Trading